Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/19/2018 10:27:39 AM - Followers: 69 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3236 hang o heavymetal 03/19/18 10:27:39 AM
#3235   A lot! Anesthesia 2007 03/18/18 04:46:46 PM
#3234   Its about pps valuation. Completed phase 1b + GBM MIKE22CA 03/18/18 02:36:22 PM
#3233   Research seems to be going really well so Anesthesia 2007 03/18/18 12:20:29 PM
#3232   I like this part of Theralase's latest PR: scoobey-do 03/18/18 11:27:09 AM
#3231   Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Anesthesia 2007 03/15/18 08:16:30 AM
#3230   time to move over here. heavymetal 03/11/18 05:40:35 PM
#3229   time to move over here. heavymetal 03/11/18 05:40:30 PM
#3228   Yes. Cannot even see the pages without logging Anniegiturmon 03/11/18 05:02:09 PM
#3227   Anyone else having trouble logging in to -3 03/11/18 04:33:47 PM
#3226   Destruction of Human Lung Cancer PR today: tedpeele 03/05/18 10:59:57 AM
#3225 CUIN2 03/02/18 09:14:02 PM
#3224   What should be of importance to this company -3 03/02/18 07:51:48 PM
#3223   Not a problem. Always respected you. Food CUIN2 02/18/18 06:19:40 PM
#3222   Best to you CUIN2 02/18/18 01:55:37 PM
#3221   CUIN2--- Thanks for keeping me in mind. rubadubdub 02/18/18 01:51:08 PM
#3220   Hi CUIN2, BIGKAHUNA57 02/18/18 10:26:30 AM
#3219   Nfusz (FUSZ) is set for golden cross/blue sky CUIN2 02/18/18 10:02:13 AM
#3218   Sent it . -3 02/17/18 12:05:58 PM
#3217   I think your expectations for TLT to be citoyen 02/16/18 03:34:57 PM
#3216   emailed him the link . He might reply -3 02/16/18 07:14:02 AM
#3215   For a sense of balance . -3 02/15/18 07:58:40 PM
#3214   Perhaps you could call him again to -3 02/15/18 06:35:29 PM
#3213   I’ve spoken with Roger several times. CUIN2 02/15/18 05:06:34 PM
#3212   CUIN.... yes...frustrating. I spoke with Roger White a citoyen 02/15/18 12:59:36 PM
#3211   No trades is very demoralizing. Not sure why Theralase CUIN2 02/13/18 11:00:36 AM
#3210   If you also look for an excelent opportunity suerte88 02/09/18 02:14:10 PM
#3209   I used the pump to dump my shares. suerte88 02/09/18 12:41:21 PM
#3208   News Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder CUIN2 02/09/18 07:30:05 AM
#3207   Gee wiz CUIN2 02/05/18 03:33:13 PM
#3206   Stealth godmode = on suerte88 02/05/18 02:56:35 PM
#3205   This will be a promising investment once they MasterSalix 02/03/18 06:42:42 PM
#3204   Strategy here has a lot to be desired. CUIN2 02/03/18 05:53:02 PM
#3203 heavymetal 02/03/18 05:44:51 PM
#3202   that explains everything. heavymetal 02/02/18 06:25:49 AM
#3201   Agree, we are even lower than that. suerte88 02/02/18 04:57:14 AM
#3200   i don't think we are under the radar anymore. heavymetal 02/02/18 03:19:43 AM
#3199   “From the words of a smart trader " CUIN2 01/24/18 12:18:36 PM
#3198   From the words of a smart trader " -3 01/24/18 10:34:14 AM
#3197   "Walk in the park"? heavymetal 01/24/18 09:26:16 AM
#3196   The clinical trial on bladder cancer has already mystic elf 01/24/18 01:44:12 AM
#3195   Sounds like someone close to the action . -3 01/23/18 06:37:55 PM
#3194   In PDT the vast majority of cancer cells mystic elf 01/23/18 02:40:02 PM
#3193   Why was DOW at 6000 in 08 and -3 01/22/18 10:27:40 AM
#3192   If that is true, then why is TLT CUIN2 01/22/18 08:51:52 AM
#3191   The beauty of nuclear acting -3 01/22/18 08:47:52 AM
#3190   Agree. Personally, I think this is a very long CUIN2 01/21/18 10:20:06 AM
#3189   Fair criticism . They need to do a -3 01/21/18 10:01:43 AM
#3188   Seeking Alpha is just a bunch of hacks MasterSalix 01/21/18 09:46:39 AM
#3187   OMG this quote where would he have got -3 01/21/18 06:37:27 AM